Innovative study with three treatment switches confirms Sandoz biosimilar etanercept has equivalent efficacy to originator

  • No clinically meaningful differences between biosimilar etanercept and the originator product in safety and efficacy over 52 weeks[1]
  • Innovative study design demonstrates switching between biosimilar etanercept and the originator product has no impact on safety and efficacy[1]
  • Sandoz biosimilar etanercept was approved by the FDA* in August 2016 and is currently under review by the EMA**

Holzkirchen, November 18, 2016 – Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, today …

/by